112 related articles for article (PubMed ID: 3468885)
1. [Serological test of carbohydrate antigen CA50 in patients with cancer of the digestive tract].
Takami H; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1987 Feb; 14(2):495-501. PubMed ID: 3468885
[TBL] [Abstract][Full Text] [Related]
2. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
Huang C; Bei L; Liu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693
[TBL] [Abstract][Full Text] [Related]
3. [Detection of DU-PAN-2 antigen (pancreatic cancer-associated antigen) in sera of patients with cancer of the digestive tract].
Takami H; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3207-14. PubMed ID: 3777958
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic value of serum CA 19-9 determination in digestive tract cancer].
Chen SB
Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):58-60. PubMed ID: 2364873
[TBL] [Abstract][Full Text] [Related]
5. [Tumor markers of pancreatic cancer].
Takami H; Hishinuma S; Shintoku J; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1985 Feb; 12(2):212-9. PubMed ID: 3855615
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic value of a new serum marker of human digestive cancer: the carbohydrate antigen 19.9; comparison with the carcinoembryonic antigen].
Olsson NO; Crimet-Montange D; Martin F
Gastroenterol Clin Biol; 1985 Mar; 9(3):206-11. PubMed ID: 3859449
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
Lucarotti ME; Habib NA; Kelly SB; Rothnie ND; Nelson O; Lindholm L; Cooper MJ; Wood CB; Williamson RC
Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358
[TBL] [Abstract][Full Text] [Related]
8. [Clinical evaluation of serum TAC-41 in various digestive cancers].
Sato S; Yamanaka T; Kimura K
Rinsho Byori; 1989 Nov; 37(11):1259-62. PubMed ID: 2601083
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic usefulness of serum levels of pancreatic oncofetal antigen (POA) and CA 19-9 in pancreatic cancers: monitoring of postoperative recurrences].
Takami H; Hishinuma S; Shintoku J; Ogata Y; Abe O
Gan No Rinsho; 1985 May; 31(6 Suppl):631-7. PubMed ID: 3861883
[TBL] [Abstract][Full Text] [Related]
10. [Determination of serum DU-PAN-2 by enzyme immunoassay in patients with various digestive cancers].
Takemori Y; Sawabu N; Satomura Y; Ohta H; Watanabe H; Okai T; Mai M; Hattori N; Akiyama T; Hashimoto T
Gan To Kagaku Ryoho; 1987 Jan; 14(1):119-26. PubMed ID: 3541791
[TBL] [Abstract][Full Text] [Related]
11. Loss of Lewis antigen expression on erythrocytes in some cancer patients with high serum CA19-9 levels.
Hirano K; Kawa S; Oguchi H; Kobayashi T; Yonekura H; Ogata H; Homma T
J Natl Cancer Inst; 1987 Dec; 79(6):1261-8. PubMed ID: 2447318
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of tumor-associated antigen of the digestive tract by monoclonal antibody].
Imai K; Hinoda Y; Yachi A
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 2):2185-90. PubMed ID: 3606145
[TBL] [Abstract][Full Text] [Related]
13. High serum levels of DUPAN2 antigen and CA19-9 in pancreatic cancer: correlation with immunocytochemical localization of antigens in cancer cells.
Suzuki Y; Ichihara T; Nakao A; Sakamoto J; Takagi H; Nagura H
Hepatogastroenterology; 1988 Jun; 35(3):128-35. PubMed ID: 3042577
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of CA 15-3 radioimmunoassay].
Takemori Y; Odani H; Watanabe H; Ohta H; Satomura Y; Okai T; Sawabu N; Mai M; Hattori N; Hashimoto T
Gan To Kagaku Ryoho; 1987 Jan; 14(1):114-8. PubMed ID: 3467654
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic usefulness of Ca 19-9 antigen in cancer of the pancreas and neoplasms of the pancreato-biliary intersection].
Robles-Diáz G; Aceves G; Galván E
Gac Med Mex; 1990; 126(2):78-82; discussion 82-3. PubMed ID: 2387490
[TBL] [Abstract][Full Text] [Related]
16. [Tumor markers for pancreatic and biliary tract cancer].
Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
[TBL] [Abstract][Full Text] [Related]
17. [Clinical investigation of carbohydrate antigen CA-50].
Ishii M; Abe O; Okura H; Okazaki N; Kawai T; Saito Y; Sawabu N; Takamizawa Y; Takeuchi T; Niitani H
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2548-55. PubMed ID: 3304170
[TBL] [Abstract][Full Text] [Related]
18. [A clinical study on the tumor associated antigen CA50 in the monitoring of genitourinary malignancies].
Li CL; Xu BZ; Chen ZZ
Zhonghua Zhong Liu Za Zhi; 1994 Mar; 16(2):148-51. PubMed ID: 7924868
[TBL] [Abstract][Full Text] [Related]
19. [Carbohydrate antigen CA 19-9: value in pancreatic pathology].
Venot J; Vincent D; Gainant A; Descottes B; Cessot F; Beck C
Gastroenterol Clin Biol; 1986 Mar; 10(3):208-10. PubMed ID: 3460925
[TBL] [Abstract][Full Text] [Related]
20. [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies].
Gang Y; Adachi I; Ohkura H; Yamamoto H; Mizuguchi Y; Abe K
Gan To Kagaku Ryoho; 1985 Dec; 12(12):2379-86. PubMed ID: 3865634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
